Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemoradiotherapy plus pucotenlimab after surgery for mucosal melanoma
ChiCTR2400093001Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pucotenlimab, temozolomide and cisplatin in mucosal melanoma (MM), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 1-year relapse-free survival rate. Started Nov 2024; status: recruiting.
02
Drugs
pucotenlimabtemozolomidecisplatin
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2400093001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093001.